Business Wire

The Estée Lauder Companies Announces Executive Leadership Team Updates

Del

Today The Estée Lauder Companies Inc. (NYSE:EL) announced the following Executive Leadership Team updates:

  • Jean-Guillaume Trottier has been promoted to Global Brand President, Jo Malone London, effective July 1, 2016. Mr. Trottier will continue to report to Mr. Demsey and serve as a member of the Company’s Executive Leadership Team.
  • Julie Van Ongevalle has been appointed Senior Vice President/Global General Manager, Origins, effective October 1, 2016. Ms. Van Ongevalle will report to Jane Hertzmark Hudis, Group President, The Estée Lauder Companies. Ms. Van Ongevalle will join the Company’s Executive Leadership Team.

Jean-Guillaume Trottier Promoted to Global Brand President, Jo Malone London

As Global General Manager, Jo Malone London since 2012, Jean-Guillaume Trottier has driven a strategy to amplify the craft of the perfumer and the brand’s pioneering approach to unexpected ingredients. Under Mr. Trottier’s leadership, brand sales have doubled globally in the last three years and Jo Malone London’s unique positioning in the luxury sensorial lifestyle space has been solidified. In addition to his continued leadership of the Jo Malone London brand as Global Brand President, Mr. Trottier will also take on select enterprise-wide responsibilities as part of this role. Additionally, Mr. Trottier has led the strategic expansion of the brand’s footprint globally, successfully launching Jo Malone London in key markets including Brazil, Korea, China, Israel and the Philippines. After joining the Company in 2004 as Brand Manager, M·A·C, France, Mr. Trottier was then appointed Vice President/General Manager, M·A·C, EMEA and U.K. in 2007. In this role, he accelerated the brand’s growth in the region with significant increases in retail sales and an elevated brand profile and positioning across key emerging and mature markets.

Mr. Demsey said, “Jean-Guillaume is a highly talented and creative leader who has effectively articulated Jo Malone London’s special equity as a British luxury brand for a global stage. From the successful growth of the freestanding store business, to cultivating the brand’s distinctly ‘giftable’ appeal, Jean-Guillaume’s unwavering vision continues to make the brand a must-have for prestige consumers around the world.”

Julie Van Ongevalle Appointed Senior Vice President/Global General Manager, Origins

Julie Van Ongevalle joined the Company in 2004 as Marketing Director, Clinique, Benelux, and during her tenure she has held brand leadership roles of increasing responsibility on multiple brands, including launching Origins in the Netherlands. Most recently, Ms. Van Ongevalle has held the position of Senior Vice President, General Manager, M·A·C, North America, where she cultivated strong retailer relationships in the brand’s largest and most tenured region globally. She established a long-term vision to expand and reinforce distribution and strengthened the field structure to provide enhanced support to the business. Prior to this, as Vice President/General Manager, M·A·C, EMEA, Ms. Van Ongevalle successfully established a strong regional team and developed strategies that enhanced consumer engagement and accelerated distribution in new and existing markets. These efforts ultimately contributed to the growth of M·A·C’s share in EMEA and established the brand as a leader in the majority of markets in the region. Ms. Van Ongevalle’s strong brand leadership experience, coupled with her multi-category and retail expertise, position her well to take the helm of the Origins brand. A successor for her current role will be announced at a later time.

“I am thrilled Julie will be assuming the leadership of Origins. Julie is a superb brand-builder possessing a keen understanding of the highly-influential Millennial consumer, as well as valuable global expertise in digital and social media and retail dynamics. I am confident she will lead this extraordinary brand to its next phase of growth around the world,” said Ms. Hertzmark Hudis.

About The Estée Lauder Companies Inc.

The Estée Lauder Companies Inc. is one of the world’s leading manufacturers and marketers of quality skin care, makeup, fragrance and hair care products. The Company’s products are sold in over 150 countries and territories under brand names including: Estée Lauder, Aramis, Clinique, Prescriptives, Lab Series, Origins, Tommy Hilfiger, M·A·C, Kiton, La Mer, Bobbi Brown, Donna Karan New York, DKNY, Aveda, Jo Malone London, Bumble and bumble, Michael Kors, Darphin, Tom Ford, Smashbox, Ermenegildo Zegna, AERIN, Marni, Tory Burch, RODIN olio lusso, Le Labo, Editions de Parfums Frédéric Malle, GLAMGLOW and By Kilian.

Contact information

The Estée Lauder Companies Inc.
Media Relations:
Alexandra Trower, (212) 572-4430
or
Investor Relations:
Dennis D’Andrea, (212) 572-4384

Om Business Wire

Business Wire
Business Wire
24 Martin Lane
EC4R 0DR London

+44 20 7626 1982http://www.businesswire.co.uk

(c) 2018 Business Wire, Inc., All rights reserved.

Business Wire, a Berkshire Hathaway company, is the global leader in multiplatform press release distribution.

Følg saker fra Business Wire

Registrer deg med din epostadresse under for å få de nyeste sakene fra Business Wire på epost fortløpende. Du kan melde deg av når som helst.

Siste saker fra Business Wire

Ferring Pharmaceuticals and MSD Announce Completion of Largest Clinical Trial Ever Conducted in Postpartum Haemorrhage22.2.2018 06:00Pressemelding

Ferring Pharmaceuticals and MSD, known as Merck & Co., Inc., Kenilworth, N.J., U.S.A., through its MSD for Mothers initiative, today announced the completion of CHAMPION (Carbetocin Haemorrhage Prevention), a global clinical trial conducted by the Human Reproduction Program (HRP) at the World Health Organization (WHO). CHAMPION is investigating whether Ferring’s proprietary and heat-stable carbetocin could offer a new solution to prevent excessive bleeding after childbirth (postpartum haemorrhage or PPH).2,3 Involving nearly 30,000 women in 10 countries, it is the largest clinical trial ever conducted in PPH.2,3 This press release features multimedia. View the full release here: http://www.businesswire.com/news/home/20180221006496/en/ Each year, 14 million mothers are affected by PPH.4 As the leading direct cause of maternal mortality, 480,000 mothers died from PPH between 2003-09.1 Even when women survive, PPH can result in the need for serious medical interventions, including surgica

The Nippon Foundation: Project to Map Ocean Floor by 2030 Now Operational22.2.2018 05:00Pressemelding

The Nippon Foundation Chairman Yohei Sasakawa announced at a press conference today that The Nippon Foundation – GEBCO Seabed 2030 Project is now operational. The Project will realize Mr. Sasakawa’s vision of mapping the entire ocean floor by 2030. The Nippon Foundation has pledged US$2 million annually, and is calling for additional support from the global ocean community. Mr. Sasakawa noted, “The Nippon Foundation alone cannot achieve the objectives of this ambitious project. We will need the support of diverse stakeholders, including maritime corporations and technical experts. It is crucial that the ocean community comes together to achieve this goal”. He was joined by leading ocean-mapping experts, who emphasized that understanding the bathymetry of the global ocean is imperative for improving maritime navigation, and also for enhancing our ability to predict climate change and monitor marine biodiversity and resources. A comprehensive map of the seafloor will assist global effort

Vertex Initiates First Phase 3 Study of VX-659, Tezacaftor and Ivacaftor as a Triple Combination Regimen for People with Cystic Fibrosis21.2.2018 21:01Pressemelding

Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced that it is initiating the first Phase 3 study of VX-659, tezacaftor and ivacaftor as an investigational triple combination regimen for people with cystic fibrosis (CF) who have one F508del mutation and one minimal function mutation. The study will enroll 360 patients, and the primary endpoint of the study is the mean absolute change from baseline in percent predicted forced expiratory volume in one second (ppFEV1) at week four of treatment. The study is designed to support the submission of a New Drug Application (NDA) in the U.S. using data from the 4-week primary efficacy endpoint together with safety data through 12 weeks of treatment. “Our goal is to bring the best triple combination to patients as rapidly as possible, and this first Phase 3 study of VX-659 in combination with tezacaftor and ivacaftor is a significant step toward that goal,” said Jeffrey Chodakewitz, M.D., Executive Vice President and Chief Medical

Universal Laser Systems® Expands Portfolio of Laser Material Processing Systems with the ULTRA Platform Series21.2.2018 18:00Pressemelding

ULTRA platform-based laser systems are designed and ideally suited for precision laser cutting, laser ablation, and laser surface modification in manufacturing, research and development, academic research and prototyping environments. Major features of the series include rapid, high-accuracy laser beam positioning, and the flexibility to be configured with 9.3 and 10.6 µm CO2 lasers and 1.06 µm fiber lasers. All lasers are air-cooled in a range of power from 10 to 150 watts for CO2 and 40 to 50 watts for fiber lasers. This press release features multimedia. View the full release here: http://www.businesswire.com/news/home/20180221005364/en/ The ULTRA 9MW offers MultiWave processing of thin materials. (Photo: Business Wire) The variety of wavelengths and power ranges make the ULTRA platforms highly effective in the areas of organic material modification, including plastic films, industrial fabrics, engineering plastics, laminating adhesives, composite materials, and many others utilized

Luxoft One of Six Companies Collaborating with Amazon Web Services to Accelerate Blockchain Adoption21.2.2018 16:30Pressemelding

Luxoft Holding Inc (NYSE:LXFT), a global IT service provider, announces today that it is collaborating with Amazon Web Services (AWS) to enable corporates to adopt blockchain and Distributed Ledger Technologies (DLT). Luxoft is one of six IT and consulting services companies to make its blockchain advisory and development services available to AWS users. “We are very excited to be working with AWS to help users engage with blockchain and DLTs,” said Vasiliy Suvorov, Vice President of Technology Strategy at Luxoft. “Blockchain is about removing data silos, improving trust and operational efficiencies. By using AWS to deploy and integrate DLTs into day-to-day processes, businesses can revolutionize how they operate.” Luxoft helps accelerate the deployment and integration of blockchain and DLT-based projects on AWS and is already working on a number of DLT projects using the cloud. For example, Luxoft is building a healthcare claims processing system for a leading healthcare provider usin

Westinghouse Electric Company to Provide Engineering Support at Vandellós 1 in Partnership with EDF21.2.2018 16:30Pressemelding

Westinghouse Electric Company and Electricité de France (EDF), in partnership, announced today that they have been awarded a contract from Empresa Nacional de Residuos Radiactivos (ENRESA), the Spanish agency responsible for radioactive waste management and nuclear plant decommissioning. The agreement covers a four-year engineering support contract for the latency phase of the dismantling and decommissioning project at Vandellós I Nuclear Power Station in Spain and includes the preparation of technical and licensing documentation. “We are extremely pleased that ENRESA has selected Westinghouse and EDF to continue supporting the decommissioning activities at Vandellós I Nuclear Power Station,” said Yves Brachet, Westinghouse vice president, Global Decommissioning, Decontamination, Remediation and Waste Management. “This contract further demonstrates Westinghouse’s global capabilities and expertise in providing innovative decommissioning solutions.” Sylvain Granger, head of EDF's decommi